VIVUS To Present New Data On Qsymia™ At 30th Annual Scientific Meeting of The Obesity Society

Sep 20, 2012, 07:00 ET from VIVUS, Inc.

MOUNTAIN VIEW, Calif., Sept. 20, 2012 /PRNewswire/ -- VIVUS, Inc. (Nasdaq:VVUS) today announced that multiple scientific abstracts will be presented at Obesity 2012, the 30th Annual Scientific Meeting of The Obesity Society, to be held September 20th to September 24th in San Antonio, Texas. The Obesity Society's Annual Scientific Meeting has grown to be one of the largest gatherings of obesity professionals worldwide.

The posters will be displayed in Exhibit Hall C of the Henry B. Gonzalez Convention Center in San Antonio from Thursday, September 20th until Saturday, September 22nd. Presenters will be at their posters on September 22, 2012 from 12:00 p.m. to 1:30 p.m. CDT.


Title: Weight Loss and Reduction in Unique Antidiabetic Medication Use in Obese Subjects With Type 2 Diabetes Mellitus Using Extended-Release
Phentermine/Topiramate Over 2 Years
Lead Authors:  T. Garvey
Poster Number: 459-P

Title: Weight Loss by Degree of Comorbidity as Assessed by the Edmonton Obesity Staging System in Subjects Receiving Extended-Release Phentermine/Topiramate
Lead Author:  L. J. Cheskin
Poster Number: 460-P

Title: Weight Loss and Changes in Blood Pressure and Triglycerides by Degree of Comorbidity in Subjects Receiving Extended-Release Phentermine/Topiramate
Lead Author:  A. M. Sharma
Poster Number: 461-P

Title: Reduction in Cardiovascular Risk Associated With Weight Loss in Three Clinical Trials of Obese Subjects Receiving Extended-Release Phentermine/Topiramate
Lead Author:  T. Church
Poster Number: 462-P

Title: Application of Proposed Treatment Algorithm Improves the Benefit/Risk Profile of Phentermine Plus Extended-Release Topiramate
Lead Authors:  R. Dvorak
Poster Number: 34-LB-P

About Qsymia

Qsymia™ (pronounced Kyoo sim ee' uh) is indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI) of 30 kg/m2 or greater (obese) or 27 kg/m2 or greater (overweight) in the presence of at least one weight-related medical condition such as high blood pressure, type 2 diabetes, or high cholesterol.

Important Safety Information

Qsymia (phentermine and topiramate extended-release) capsules CIV must not be used by women who are pregnant; by patients with eye problems (glaucoma); by patients who have been told they have an overactive thyroid; by patients taking a type of anti-depressant called MAOI; or by patients who are allergic to phentermine, topiramate, or any of the ingredients in Qsymia.

Qsymia can harm your unborn baby.  If you take Qsymia while you are pregnant, your baby has a higher risk for birth defects called cleft lip and cleft palate. You should have a negative pregnancy test before taking Qsymia and every month while taking Qsymia. Use effective birth control (contraception) consistently while taking Qsymia. If you become pregnant while taking Qsymia, you should stop taking Qsymia immediately and contact your healthcare provider right away.

Qsymia can also increase your heart rate, may affect your vision and cause an increased pressure in your eyes, and may cause disturbances in concentration, attention, memory or speech.  Topiramate, a component of Qsymia, may cause you to have suicidal thoughts or actions, and may cause depression. You should call your healthcare provider if any of these symptoms occur.

The most common side effects seen in Qsymia clinical studies were tingling in the hands and feet, dizziness, change in taste, trouble sleeping, constipation, and dry mouth.


STENDRA™ is a prescription medicine used to treat erectile dysfunction (ED). STENDRA is licensed from Mitsubishi Tanabe Pharma Corporation. VIVUS has development and commercial rights to STENDRA for the treatment of sexual dysfunction worldwide with the exception of certain Asian Pacific Rim countries.  In South Korea, STENDRA is approved and is marketed by JW Pharma under the brand name Zepeed. 

Important Safety Information

Do not take STENDRA (avanafil) if you take nitrates, often prescribed for chest pain, as this may cause a sudden, unsafe drop in blood pressure. Tell your healthcare provider about all the medicines you take and discuss your general health status to ensure that you are healthy enough to engage in sexual activity. If you experience chest pain, nausea, or any other discomforts during sex, seek immediate medical help.

In the rare event of an erection lasting more than 4 hours, seek immediate medical help to avoid long-term injury. STENDRA in combination with other treatments for erectile dysfunction is not recommended. STENDRA does not protect against sexually transmitted diseases, including HIV. The most common side effects of STENDRA are headache, flushing, runny nose and congestion.


VIVUS® is a biopharmaceutical company commercializing and developing innovative, next-generation therapies to address unmet needs in obesity, sleep apnea, diabetes and sexual health for U.S., Europe and other world markets. VIVUS has two products currently approved in the U.S.; Qsymia (phentermine and topiramate extended-release) capsules CIV and Stendra (avanafil) tablets.  Qsymia is also in phase 2 clinical development for the treatment of type 2 diabetes and obstructive sleep apnea. For more information about the company, please visit

Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as "anticipate," "believe," "forecast," "estimate," "expect," "intend," "likely," "may," "plan," "potential," "predict," "opportunity" and "should," among others. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, our lack of commercial experience with Qsymia in the U.S.; the timing of initiation and completion of the clinical studies required as part of the approval of Qsymia by the United States Food and Drug Administration, or FDA; the response from the FDA to the data that VIVUS will submit relating to post-approval clinical studies; the impact of the indicated uses and contraindications contained in the Qsymia label and the REMS requirements; the impact of distribution of Qsymia through a certified pharmacy network; that we may be required to provide further analysis of previously submitted clinical trial data; our response to questions and requests for additional information including additional pre-clinical or clinical studies from the European Medicines Agency, or EMA, and the Committee for Medicinal Products for Human Use, or CHMP, for the Marketing Authorization Application, or MAA, for Qsymia; our ability to successfully commercialize or establish a marketing partnership for avanafil, which will be marketed in the U.S. under the name STENDRA, or our partner's ability to obtain and maintain regulatory approval to manufacture and adequately supply avanafil for commercial use; our history of losses and variable quarterly results; substantial competition; risks related to the failure to protect our intellectual property and litigation in which we may become involved; uncertainties of government or third party payer reimbursement; our reliance on sole source suppliers; our limited sales and marketing and manufacturing experience; our reliance on third parties and our collaborative partners; our failure to continue to develop innovative investigational drug candidates and drugs; risks related to the failure to obtain FDA or foreign authority clearances or approvals and noncompliance with FDA or foreign authority regulations; our ability to demonstrate through clinical testing the safety and effectiveness of our investigational drug candidates; the timing of initiation and completion of clinical trials and submissions to foreign authorities; the volatility and liquidity of the financial markets; our liquidity and capital resources; and our expected future revenues, operations and expenditures. As with any pharmaceutical in development, there are significant risks in the development, the regulatory approval, and commercialization of new products. There are no guarantees that our response to the CHMP's 180-day list of outstanding issues and subsequent meetings and communications will be sufficient to satisfy the CHMP's safety concerns regarding Qsymia, that the foreign authorities will not require us to conduct any additional prospective studies or retrospective observational studies, or that any product will receive foreign regulatory approval for any indication or prove to be commercially successful. VIVUS does not undertake an obligation to update or revise any forward-looking statements. Investors should read the risk factors set forth in VIVUS' Form 10-K for the year ending December 31, 2011, and periodic reports filed with the Securities and Exchange Commission.